Signet Announces the Release of an sAPPbeta Antibody
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Signet Laboratories, Inc. has announced the availability of a polyclonal antibody specific for sAPPbeta, a cleavage product of amyloid precursor protein.
"Quantitative analysis of the cleavage products generated during the processing of amyloid precursor protein is critical to the understanding of the pathogenesis of Alzheimer's disease," said Joe Bertelsen, Neuroscience Product Manager, Signet Laboratories, Inc.
"Signet's sAPPbeta specific antibody, the first of its kind commercially available to AD researchers, will serve as a powerful tool in the development of diagnostic and therapeutic strategies for this devastating disease."
